FRANCE – Kayentis, a Grenoble, France-based provider of electronic Clinical Outcome Assessment (eCOA) and Decentralized Clinical Trial (DCT) solutions, raised additional €5M in funding.
The round was led by LBO France, Extens and Bpifrance. Together, they contributed €2.2M in increased capital. Kayentis obtained the remaining €2.8M in bank loans.The company intends to use the funds to scale-up its operations in North America to support clinical trials.Led by CEO Guillaume Juge, Kayentis is a provider of eCOA (electronic Clinical Outcome Assessment) and Decentralized Clinical Trial solutions (DCTs), which allow pharma, biotech and CROs to bring efficiency and quality to the collection of clinical trial data from both patients and sites. Since 2003, Kayentis has been active in clinical development, with a specialization in eCOA solutions for phases II/III across a broad range of therapeutic areas. Over the years, it has developed a range of services and has enlarged its portfolio beyond eCOA solutions to support the new normal of decentralized and hybrid trials. Whilst Kayentis is currently focusing on expanding its US operations, where US-based sponsor study teams lead one-third of its projects, the company is also active across Europe and Asia. Among its clients are several big pharma, as well as mid-size and smaller biotech companies. The company has conducted digital data collection for over 280 clinical trials in 85 countries (18,000 sites and 98,000 patients), employing 120 languages.It has offices in the US (Boston), France (Grenoble) and Japan (Tokyo), and currently employs 185 staff.28/03/2023
